SERUM CYTOKINE LEVELS AFTER HLA-IDENTICAL BONE MARROW TRANSPLANTATION1
- 1 October 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (7) , 863-871
- https://doi.org/10.1097/00007890-199810150-00009
Abstract
Altered profiles of cytokine production are observed after bone marrow transplantation (BMT). The presence of certain cytokines in serum can be indicative for BMT-related complications, such as graft-versus-host disease (GVHD) and infections. The putative correlation between abnormal serum cytokine levels and BMT-related complications was further analyzed in this retrospective study. Serum levels of a panel of cytokines and cytokine-associated molecules (i.e., interleukin [IL]-1α, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-1 receptor antagonist, and the soluble α chain of the IL-2 receptor [sIL-2Rα]) were assessed in 329 sera of 46 patients who had undergone HLA-identical or autologous BMT. Serum cytokine levels of the BMT donor and of the patients before BMT and at different time points during the post-BMT period were measured. The results were correlated with relapse, acute GVHD, chronic GVHD, and infections. Serum levels of IL-1α, IL-1β, IL-4, and IL-12 were undetectable. The transplantation regimen itself causes a significant rise in IL-10 and sIL-2Rα levels in patients receiving allogeneic bone marrow. In the post-BMT period, increased IL-6 serum levels were significantly correlated with infections. Increased IL-10 levels were significantly correlated with acute graft-versus-host disease, chronic GVHD, and infections. Increased sIL-2Rα levels were correlated with chronic GVHD, as were IL-1 receptor antagonist levels. During the post-HLA-identical BMT period, the serum cytokine levels of IL-6 were enhanced during infections, whereas the sIL-2Rα levels were increased during chronic GVHD. The serum levels of IL-10 and of the cytokine-related molecule IL-1ra were enhanced during both infections and chronic GVHD. These results further substantiate the complex cytokine cascade that is initiated by the conditioning regimen and that evolves further in reaction to BMT-related complications and their treatments.Keywords
This publication has 49 references indexed in Scilit:
- Effect of CD80 and CD86 blockade and anti‐interleukin‐12 treatment on mouse acute graftversus‐host diseaseEuropean Journal of Immunology, 1996
- SOLUBLE INTERLEUKIN-6 RECEPTORS IN HEMATOLOGY PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION1Transplantation, 1996
- INHIBITORY EFFECTS OF RECOMBINANT HUMAN INTERLEUKIN 10 ON DISEASE MANIFESTATIONS IN A P→F1 MODEL OF ACUTE GRAFT VERSUS HOST DISEASETransplantation, 1995
- Cytokine Gene Expression after Allogeneic Bone Marrow TransplantationLeukemia & Lymphoma, 1995
- Soluble Interleukin-2 Receptor Levels in Cytomegalovirus Disease and Graft Versus Host Disease after T-Lymphocyte Depleted Bone Marrow Transplantation for Hematological NeoplasiasLeukemia & Lymphoma, 1994
- INTERLEUKIN-1 IS A CRITICAL EFFECTOR MOLECULE DURING CYTOKINE DYSREGULATION IN GRAFT VERSUS HOST DISEASE TO MINOR HISTOCOMPATIBILITY ANTIGENS1Transplantation, 1993
- Interleukin-10Annual Review of Immunology, 1993
- Differential cytokine expression in acute and chronic murine graft‐versus‐host‐diseaseEuropean Journal of Immunology, 1993
- Hyper IgE in stimulatory graft- versus-host disease: role of interleukin-4Clinical and Experimental Immunology, 1991
- Interleukin-6: An OverviewAnnual Review of Immunology, 1990